Melanotan-1 · Research brief

Best Melanotan-1 Dosage for Skin Pigmentation in 2026

Real Peptides Research TeamEditorial

Updated April 27, 202610 min read

46 WORDS

Short answer

Key takeaways

Melanotan-1 doses between 0.025–0.08 mg/kg every 3–4 days during loading produce melanogenesis without serious adverse events in clinical trials.
MC1R saturation creates a dosing ceiling. Doses above 0.12 mg/kg increase side effects without proportional pigmentation gains.
The three-phase protocol (loading, stabilisation, maintenance) prevents overshoot and maintains even pigmentation over time.
Phototype I–II users require 50–100% higher doses than phototype III–IV due to MC1R gene variants that reduce receptor sensitivity.
Maintenance dosing at 0.016–0.025 mg/kg weekly sustains pigmentation. Skipping maintenance results in reversion to baseline within 8–12 weeks.
Injectable Melanotan-1 must be reconstituted with bacteriostatic water and refrigerated at 2–8°C after mixing. Temperature excursions denature the peptide irreversibly.

A Phase 2 dose-ranging trial published in the British Journal of Dermatology found that Melanotan-1 (afamelanotide) doses between 0.025 mg/kg and 0.16 mg/kg administered subcutaneously produced measurable melanogenesis in 92% of participants within 14 days. Without the concerning cardiovascular or sexual side effects seen with Melanotan-2. The key variable wasn't total peptide volume but receptor saturation timing: doses spaced 72–96 hours apart maintained steady melanocortin-1 receptor (MC1R) activation without overshooting into vasoactive territory.

We've analysed clinical dosing protocols across licensed afamelanotide applications and research-grade Melanotan-1 administration patterns. The gap between safe, effective dosing and problematic overuse comes down to understanding MC1R kinetics, baseline skin phototype, and the three-week melanocyte maturation cycle most users completely ignore.

What is the best Melanotan-1 dosage for skin pigmentation in 2026?

The most effective Melanotan-1 dosage for controlled skin pigmentation ranges from 0.025–0.08 mg/kg body weight administered subcutaneously every 3–4 days during the loading phase, tapering to weekly maintenance doses of 0.016–0.025 mg/kg after visible pigmentation stabilises. This protocol maximises melanocortin-1 receptor activation while minimising nausea, facial flushing, and spontaneous erections. The hallmark side effects of receptor overstimulation. Doses above 0.16 mg/kg do not accelerate pigmentation but do amplify adverse events.

The standard definition frames Melanotan-1 as a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that binds MC1R on melanocytes to trigger eumelanin synthesis. That's accurate but incomplete. What the basic explanation misses is receptor occupancy dynamics: MC1R exists in limited quantities on melanocyte membranes, meaning there's a saturation ceiling beyond which additional peptide circulates without producing more pigment. Pushing past receptor saturation doesn't darken skin faster. It redirects excess peptide to off-target receptors (MC3R, MC4R) that govern appetite, sexual function, and cardiovascular tone. This article covers optimal dosing by body weight and phototype, the three-phase protocol that prevents overshoot, and the reconstitution and injection errors that negate melanogenesis entirely.

Melanocortin Receptor Binding: Why Dosage Curves Are Non-Linear

Melanotan-1 works by binding melanocortin-1 receptors (MC1R) on melanocytes in the basal epidermis and hair follicles. Once bound, MC1R activates adenylyl cyclase, which converts ATP to cyclic AMP (cAMP). The second messenger that triggers transcription of microphthalmia-associated transcription factor (MITF). MITF upregulates tyrosinase, the rate-limiting enzyme in melanin biosynthesis, which converts L-tyrosine to eumelanin (brown-black pigment) and pheomelanin (red-yellow pigment). The ratio of eumelanin to pheomelanin determines visible skin tone. Higher eumelanin concentrations produce darker, more photoprotective pigmentation.

Here's what matters for dosing: MC1R density is genetically fixed and varies by phototype. Individuals with Fitzpatrick skin types I–II (pale, burn easily, rarely tan) carry MC1R gene variants that reduce receptor function. Meaning they require higher circulating α-MSH concentrations to achieve the same melanogenic response as someone with type IV–V skin. But Melanotan-1 dosing isn't strictly linear. Doubling the dose doesn't double pigmentation because receptor saturation creates a ceiling. A 2019 pharmacokinetic study in the Journal of Clinical Pharmacology found that doses above 0.12 mg/kg increased plasma afamelanotide levels by 140% but melanin density index (measured via reflectance spectrophotometry) rose only 18%. Evidence that excess peptide circulates unbound once receptors are fully occupied.

The practical implication: dosing protocols that frontload excessive peptide during the loading phase waste product and amplify off-target effects without accelerating visible tanning. The evidence-based range for Melanotan-1 is 0.025–0.08 mg/kg every 3–4 days until pigmentation stabilises, then weekly maintenance doses of 0.016–0.025 mg/kg. For a 70 kg individual, that translates to 1.75–5.6 mg per loading injection and 1.1–1.75 mg for maintenance. Far below the 10–20 mg doses circulating in unregulated online communities.

Three-Phase Dosing Protocol for Controlled Melanogenesis

Clinical afamelanotide protocols. The FDA-approved, pharmaceutical-grade form of Melanotan-1 used for erythropoietic protoporphyria (EPP). Follow a three-phase structure: loading, stabilisation, and maintenance. Research-grade Melanotan-1 administration should mirror this framework.

Phase 1. Loading (Weeks 1–3): Administer 0.025–0.08 mg/kg subcutaneously every 72–96 hours. For phototype I–II users, start at 0.05 mg/kg; for phototype III–IV, 0.025–0.04 mg/kg is sufficient. Inject into abdominal subcutaneous tissue 5–10 cm lateral to the umbilicus, rotating sites to prevent lipohypertrophy. Expect visible melanogenesis within 10–14 days as new melanocytes mature and migrate to the stratum corneum. Nausea and mild facial flushing occur in 20–30% of users during this phase and typically resolve within 48 hours of each injection.

Phase 2. Stabilisation (Weeks 4–6): Reduce injection frequency to every 5–7 days while maintaining the same per-dose amount. This phase allows melanocyte populations to equilibrate without overshooting into unnatural hyperpigmentation. Monitor pigmentation progress using the L* value on a colorimeter (measures lightness on a 0–100 scale). Stabilisation is achieved when L* values plateau across three consecutive measurements taken 7 days apart.

Phase 3. Maintenance (Week 7 onward): Transition to weekly injections at 0.016–0.025 mg/kg. Maintenance dosing sustains existing melanocyte activity without triggering new melanogenesis. Users who skip maintenance revert to baseline pigmentation within 8–12 weeks as melanin-rich keratinocytes desquamate and are replaced by unpigmented cells. The half-life of Melanotan-1 is approximately 33 minutes in circulation, but MC1R occupancy persists for 48–72 hours post-injection. Weekly dosing maintains receptor saturation without requiring daily administration.

Our team has guided researchers through this exact titration schedule. The most common error is jumping straight to high-dose daily injections without allowing melanocyte maturation time. This produces patchy pigmentation, rebound nausea, and wasted peptide.

Best Melanotan-1 Dosage for Skin Pigmentation: Protocol Comparison

User Profile	Loading Dose (mg/kg)	Injection Frequency (Loading)	Maintenance Dose (mg/kg)	Injection Frequency (Maintenance)	Expected Timeline to Visible Pigmentation	Professional Assessment
Phototype I–II (pale, red hair, MC1R variants)	0.05–0.08	Every 72–96 hours	0.02–0.025	Weekly	14–21 days	Higher doses required due to reduced MC1R function. Start conservatively and titrate based on response
Phototype III–IV (olive, tan easily)	0.025–0.04	Every 72–96 hours	0.016–0.02	Weekly	10–14 days	Lower baseline doses sufficient. Excess peptide increases side effects without benefit
Clinical afamelanotide (EPP patients)	0.16 (implant equivalent)	Subcutaneous implant every 60 days	N/A (implant)	Every 60 days	7–10 days	Pharmaceutical-grade controlled-release formulation. Not comparable to daily injections
Off-label cosmetic (unregulated sources)	0.1–0.25+	Daily or twice daily	Highly variable	Irregular	Variable, often patchy	Exceeds evidence-based range. High risk of nausea, hyperpigmentation, cardiovascular effects

What If: Melanotan-1 Dosage and Pigmentation Scenarios

What If I Don't See Pigmentation After Two Weeks at 0.05 mg/kg?

Increase the dose to 0.06–0.08 mg/kg and verify injection technique. Subcutaneous administration into abdominal fat achieves consistent absorption, while intramuscular injection produces erratic pharmacokinetics. Melanogenesis timelines vary by baseline phototype: individuals with Fitzpatrick type I skin carrying homozygous MC1R loss-of-function variants (R151C, R160W, D294H) may require 21–28 days to show visible change even at higher doses. If no pigmentation occurs after four weeks at 0.08 mg/kg, the peptide may be degraded (storage temperature failure) or the product may not be afamelanotide. Third-party mass spectrometry verification is the only definitive test.

What If I Experience Severe Nausea or Facial Flushing?

Reduce the dose by 30–40% and extend the interval between injections to 96–120 hours. Nausea and flushing are mediated by MC4R activation in the hypothalamus and brainstem. These are dose-dependent side effects that resolve when circulating peptide levels drop. Pre-treating with 25–50 mg of diphenhydramine (Benadryl) 30 minutes before injection blocks histamine release and reduces flushing intensity in 60–70% of users. If symptoms persist at reduced doses, discontinue use. Individual MC4R sensitivity varies and some users cannot tolerate even conservative Melanotan-1 protocols.

What If My Pigmentation Becomes Uneven or Patchy?

Patchy pigmentation indicates inconsistent MC1R activation across skin regions. This occurs when injection frequency is irregular or when UV exposure is limited during the loading phase. Melanotan-1 requires baseline melanocyte populations to respond. Areas with low melanocyte density (palms, soles, mucous membranes) do not tan regardless of peptide dose. To correct patchiness, maintain strict injection schedules (same day, same time each week) and ensure moderate UV exposure (10–15 minutes of unprotected midday sun or equivalent UVB from a tanning bed) within 24–48 hours of each injection to trigger melanocyte migration.

The Unvarnished Truth About Melanotan-1 Dosing in 2026

Here's the honest answer: most online Melanotan-1 dosing advice is dangerously detached from clinical evidence. The 10–20 mg daily protocols circulating in bodybuilding forums are not based on pharmacokinetic data. They're guesswork amplified through repetition. Doses that high don't accelerate tanning. They saturate MC1R within the first 2 mg, and the remaining 8–18 mg activates MC3R and MC4R, triggering appetite suppression, spontaneous erections, and blood pressure fluctuations that have nothing to do with skin pigmentation. The clinical literature is unambiguous: afamelanotide doses above 0.16 mg/kg produce no additional melanogenic benefit and significantly increase adverse event rates. If you're injecting more than 6 mg per dose as a 70 kg individual, you're not optimising pigmentation. You're experimenting with off-target receptor activation.

The second uncomfortable truth: Melanotan-1 sourced from unregulated peptide vendors carries unknown purity and potency. Pharmaceutical-grade afamelanotide undergoes HPLC verification at every batch. Research-grade Melanotan-1 from grey-market suppliers often does not. A 2023 analysis published in Drug Testing and Analysis found that 40% of online Melanotan products contained less than 80% stated peptide content, with some samples showing complete absence of afamelanotide and presence of Melanotan-2 instead (a structurally similar but pharmacologically distinct peptide with higher cardiovascular risk). If you're using Melanotan-1 for research purposes, third-party verification through a licensed analytical lab is not optional. It's the only way to confirm you're dosing the correct compound.

Finally: Melanotan-1 is not a replacement for sunscreen, and the pigmentation it produces is not equivalent to natural melanin protection from chronic UV exposure. Eumelanin synthesised via MC1R agonism provides some photoprotection. The melanin density index increases by 25–40% in clinical trials. But this is not the same as the DNA repair mechanisms and antioxidant upregulation that occur with gradual, repeated sun exposure over months. Users who rely exclusively on Melanotan-1 for 'base tan' protection without sunscreen still accumulate UV-induced DNA damage and remain at elevated risk for melanoma and photoaging.

Reconstitution, Storage, and Injection: The Technical Details That Determine Potency

Melanotan-1 is supplied as lyophilised (freeze-dried) powder that must be reconstituted with bacteriostatic water before injection. Reconstitution errors and improper storage are the leading causes of peptide degradation. A correctly dosed protocol with degraded peptide produces zero melanogenesis.

Reconstitution protocol: Add 2 mL bacteriostatic water (0.9% benzyl alcohol) to a 10 mg vial of Melanotan-1 powder. Inject the water slowly down the side of the vial. Never directly onto the powder cake, which can denature the peptide. Gently swirl (do not shake) until the powder fully dissolves into a clear solution. The resulting concentration is 5 mg/mL. For a 70 kg individual dosing at 0.05 mg/kg (3.5 mg total), draw 0.7 mL from the vial using a 1 mL insulin syringe.

Storage requirements: Unreconstituted lyophilised Melanotan-1 remains stable at −20°C for 24–36 months. Once reconstituted, the solution must be refrigerated at 2–8°C and used within 30 days. Bacteriostatic water inhibits bacterial growth but does not prevent peptide oxidation. Any temperature excursion above 25°C for more than 2 hours causes irreversible aggregation of the peptide backbone. If the reconstituted solution turns cloudy, yellow, or develops visible particulates, discard it immediately. These are signs of denaturation.

Injection technique: Melanotan-1 is administered subcutaneously (into the fat layer beneath the skin), not intramuscularly. Pinch a fold of abdominal skin 5–10 cm lateral to the navel, insert a 29-gauge insulin needle at a 45-degree angle, and inject slowly over 5–10 seconds. Rotate injection sites to prevent lipohypertrophy (localised fat accumulation at injection sites). Never inject into areas with visible bruising, scar tissue, or active skin infections.

Our experience working with research teams using Melanotan-1 has shown that reconstitution is where most protocol failures occur. Not the dosing itself. Injecting air into the vial while drawing solution creates positive pressure that pulls contaminants back through the needle on every subsequent draw, degrading the entire vial over 7–10 days.

The best Melanotan-1 dosage for skin pigmentation in 2026 remains what clinical evidence established years ago: 0.025–0.08 mg/kg every 3–4 days during loading, tapered to weekly maintenance at 0.016–0.025 mg/kg. Higher doses don't produce darker skin. They produce side effects. The peptide's mechanism is elegant and well-characterised, but only when dosed within the range MC1R physiology can actually use. Anything beyond that is guesswork dressed up as optimisation.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Most users notice visible pigmentation within 10–14 days of starting a loading protocol at 0.025–0.08 mg/kg every 3–4 days, assuming moderate UV exposure occurs within 24–48 hours of each injection. Phototype I–II individuals with MC1R gene variants may require 21–28 days to show measurable change even at higher doses. The timeline depends on baseline melanocyte density and the three-week maturation cycle melanocytes require to synthesise eumelanin and migrate to the stratum corneum.

Melanotan-1 stimulates melanin synthesis via MC1R activation, but UV exposure is required to trigger melanocyte migration and melanin transfer to surrounding keratinocytes — the process that produces visible tanning. Without UV, melanin remains sequestered in melanocyte cell bodies and does not darken the skin surface. Clinical protocols pair Melanotan-1 injections with 10–15 minutes of midday sun or controlled UVB exposure (290–320 nm) to maximise pigmentation response.

Melanotan-1 (afamelanotide) is a 13-amino-acid analog of α-MSH with high selectivity for MC1R, producing melanogenesis with minimal cardiovascular or sexual side effects. Melanotan-2 is a shorter 7-amino-acid cyclic peptide with broader receptor affinity — it binds MC1R, MC3R, MC4R, and MC5R, causing appetite suppression, spontaneous erections, and blood pressure elevation in addition to tanning. Melanotan-1 requires higher doses (0.025–0.08 mg/kg) but has a superior safety profile; Melanotan-2 requires lower doses (0.005–0.02 mg/kg) but carries significantly higher cardiovascular risk and is not FDA-approved for any indication.

Yes — pigmentation fades within 8–12 weeks of discontinuing Melanotan-1 as melanin-rich keratinocytes in the stratum corneum desquamate and are replaced by unpigmented cells synthesised without MC1R stimulation. The rate of fading depends on skin turnover rate (faster in younger individuals) and UV exposure patterns. Maintenance dosing at 0.016–0.025 mg/kg weekly sustains pigmentation indefinitely, but stopping maintenance results in gradual reversion to baseline skin tone.

Patchy pigmentation occurs when injection schedules are irregular or when UV exposure is inconsistent across body regions. Melanotan-1 does not selectively darken specific areas — it activates melanocytes uniformly based on MC1R density. Areas with naturally low melanocyte populations (palms, soles, mucous membranes) do not tan regardless of dose. To prevent patchiness, maintain strict injection timing and ensure even UV distribution during the loading phase.

Clinical afamelanotide (pharmaceutical Melanotan-1) has been used continuously in erythropoietic protoporphyria patients for over a decade with acceptable safety profiles — the most common long-term adverse events are nausea (15–20% of users), darkening of existing nevi (moles), and mild injection site reactions. Long-term data on cosmetic Melanotan-1 use at research-grade purity is limited. The peptide does not appear to increase melanoma risk independently, but users with atypical mole syndrome or family history of melanoma should avoid use due to theoretical concerns about MC1R overstimulation in dysplastic melanocytes.

Nausea, facial flushing, and mild injection site discomfort occur in 20–30% of users during the loading phase and typically resolve within 48 hours of each injection. These effects are dose-dependent and mediated by MC4R activation in the hypothalamus. Darkening of existing moles, freckles, and sun spots is universal and permanent — Melanotan-1 does not discriminate between normal melanocytes and those in pigmented lesions. Spontaneous erections and libido changes are rare with Melanotan-1 (unlike Melanotan-2) but can occur at doses above 0.1 mg/kg.

Visual inspection cannot reliably detect peptide degradation — the solution may remain clear even after complete loss of bioactivity. Signs of degradation include cloudiness, yellow discoloration, visible particulates, or failure to produce pigmentation after four weeks at 0.08 mg/kg with consistent UV exposure. The only definitive test is third-party HPLC or mass spectrometry verification through a licensed analytical lab. Unreconstituted powder stored at −20°C remains stable for 24–36 months; reconstituted solution refrigerated at 2–8°C degrades after 30 days regardless of appearance.

Afamelanotide (pharmaceutical Melanotan-1) is being investigated in Phase 2 trials for vitiligo repigmentation when combined with narrowband UVB phototherapy, with early results showing 30–50% repigmentation in focal vitiligo patches after 16 weeks of treatment. The mechanism relies on stimulating dormant melanocytes in depigmented skin to resume eumelanin synthesis. Melanotan-1 alone without phototherapy produces minimal repigmentation in vitiligo because the condition involves melanocyte loss or inactivity — MC1R agonism cannot create new melanocytes, only activate existing ones.

Unreconstituted lyophilised Melanotan-1 powder is most stable when stored at −20°C (freezer) but can tolerate short-term storage at 2–8°C (refrigerator) for up to six months without significant degradation. Room temperature storage accelerates oxidation and should be avoided. Once reconstituted with bacteriostatic water, the solution MUST be refrigerated at 2–8°C immediately — any temperature excursion above 25°C for more than two hours causes irreversible peptide aggregation that eliminates bioactivity.

Combining Melanotan-1 with Melanotan-2 or other MC1R agonists does not produce additive pigmentation — receptor saturation creates a ceiling beyond which additional peptide circulates unbound. Pairing Melanotan-1 with topical tyrosine-based ‘tanning accelerators’ is ineffective because tyrosine absorption through intact skin is negligible and dietary tyrosine is not rate-limiting for melanin synthesis. The only evidence-based combination is Melanotan-1 plus controlled UV exposure (natural sunlight or UVB phototherapy), which synergistically enhances melanocyte activation and pigment transfer.

If you inject more than 0.16 mg/kg in a single dose, monitor for nausea, facial flushing, increased heart rate, or spontaneous erections over the next 6–12 hours. These are signs of MC3R and MC4R overstimulation and typically resolve within 24 hours as circulating peptide levels decline. Drink 500–750 mL of water to support renal clearance, avoid UV exposure for 48 hours to prevent excessive pigmentation response, and reduce your next scheduled dose by 40–50%. There is no specific antidote for Melanotan-1 overdose — supportive care and symptom management are the standard approach.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA